Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) shares reached a new 52-week low on Thursday. The company traded as low as GBX 32 and last traded at GBX 32.50, with a volume of 27,079 shares changing hands. The stock had previously closed at GBX 36.
Faron Pharmaceuticals Oy Stock Performance
The company’s 50 day simple moving average is GBX 37.04 and its 200 day simple moving average is GBX 40.85. The company has a debt-to-equity ratio of 154.15, a quick ratio of 1.09 and a current ratio of 2.40. The stock has a market cap of £65.94 million, a PE ratio of -2.82 and a beta of 1.12.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
